Meta Platforms Inc. (NASDAQ: META) seems to be able to do no wrong. Despite all of its regulatory troubles and obvious flip-flops on policies around who is in charge in Washington, D.C., the parent of Facebook and Instagram just keeps growing and growing after each earnings report.
Oggonomics has tracked about two dozen analyst calls with a very positive tone after the social media giant’s earnings report. Many of the reports echo each other, but the one trend that is impossible to ignore is that Wall Street believes Meta’s stock is going much higher.
The late-Thursday reaction still had shares up 1.5% at $685.75, bit shares briefly hit an all-time high of $710.79 early on after the opening bell. Meta’s market cap at the current price is just above $1.7 trillion.
While Facebook and its other entities under Meta have been investing in AI, the recent dance-partner shift by Wall Street to DeepSeek and away from NVIDIA did not hurt Meta. Its stock is actually up from the end of last week.
The reality is that most analysts have a very positive rating and high upside target for Meta Platforms. Benchmark raised its rating to Buy from Hold with a $820 price target as revenue and operating expense guidance appears to set a conservative 2025 bar for expectations.
Again, most of the analyst calls mirror each other for the most part. Some are different but the universal belief seen here is that analysts are even that much more positive for Meta Platforms going forward. Here is a summary of the reiterated ratings (most with price target hikes) below:
- Barclays (Overweight) target to $705 from $630
- Bernstein (Outperform) target to $800 from $685
- BofA Securities (Buy) price objective to $765 from $710
- BMO Capital Markets (Market Perform) target to $610 from $530
- Cantor Fitzgerald (Overweight) target to $790 from $720
- Citigroup (Buy) target to $780 from $753
- DA Davidson (Buy) target to $800 from $700
- Goldman Sachs (Buy) target to $765 from $688
- JMP Securities (Outperform) target reiterated at $750
- JPMorgan (Overweight) reiterated at $725
- Mizuho (Outperform) target to $750 from $675
- Oppenheimer (Outperform) target to $800 from $650
- Piper Sandler (Overweight) target to $775 from $670
- Pivotal Research (Buy) target to $875 from $800
- Raymond James (Buy) target to $800 from $725
- RBC Capital Markets (Outperform) target to $800 from $700
- Robert W. Baird (Outperform) target to $750 from $680
- Rosenblatt (Buy) target to $846 from $811
- Stifel (Buy) target to $740 from $692
- Susquehanna (Positive) target to $800 from $675
- Truist (Buy) target to $770 from $700
- Wedbush Securities (Outperform) target to $770 from $700
- Wells Fargo (Overweight) target to $752 from $685
All ratings and price targets are from the firms mentioned above. Oggonomics does not have its own internal price targets nor any formal rating on Meta and the companies mentioned in this report.
